Strategic Investment ProSomnus has secured substantial funding and recently attracted a $38M strategic investment from Catalio Capital Management, signaling strong growth momentum and potential for expanded sales channels and partnerships to scale Smart Sleep Medicine and RPMO2 platform deployments.

Connected Care Expansion Recent collaboration with MonitAir to enhance connected care for OSA suggests opportunities to cross-sell monitoring services, remote patient monitoring features, and integrated data diagnostics to existing and new provider networks.

Market Validation Consistent Inc. 5000 recognition and favorable manufacturing rankings reinforce credibility with payers, clinics, and health systems, making a compelling case for expanding adoption of non-CPAP OAT solutions among physician groups and integrated delivery networks.

Insurance Coverage FDA-cleared, patented devices already covered by commercial insurance, Medicare, and TRICARE with broad coverage across 200M lives indicate a favorable reimbursement environment to target large-scale payer-led deployments and provider contracts.

Scale-ready Platform A growing clinical evidence base and multi-night physiologic monitoring via RPMO2 position ProSomnus to upsell expanded OSA treatment workflows, clinical decision support, and data-driven outcomes reporting to sleep clinics, hospitals, and telehealth platforms.